Trial Profile
The efficacy and safety of two doses of strontium ranelate (1g and 2g per day) versus placebo administered orally for 3 years in the treatment of knee osteoarthritis. A prospective multicentre, international, double-blind, placebo-controlled study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Sep 2020
Price :
$35
*
At a glance
- Drugs Strontium ranelate (Primary)
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Acronyms POLKA; SEKOIA
- Sponsors Servier
- 22 Aug 2020 Results assessing the utility of two alternative statistical modelling methods for monitoring KOA progression presented at the 2020 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
- 22 Apr 2018 Results (n=1206) assessing data from follow-up study planned over 5-year, conducted in patients with a primary knee osteoarthritis having participated in the previous CL3-12911-018 study, were presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
- 05 Apr 2014 Results of an analysis of the placebo arm presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.